KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Equity Ratio for 16 consecutive years, with 0.23 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 6.14% to 0.23 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.23, a 6.14% increase, with the full-year FY2024 number at 0.18, up 264.64% from a year prior.
  • Equity Ratio was 0.23 for Q3 2025 at Halozyme Therapeutics, up from 0.22 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.24 in Q3 2021 to a low of 0.05 in Q4 2023.
  • A 5-year average of 0.14 and a median of 0.13 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: crashed 78.11% in 2022, then soared 264.64% in 2024.
  • Halozyme Therapeutics' Equity Ratio stood at 0.18 in 2021, then crashed by 48.29% to 0.09 in 2022, then crashed by 47.56% to 0.05 in 2023, then skyrocketed by 264.64% to 0.18 in 2024, then increased by 28.67% to 0.23 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Equity Ratio are 0.23 (Q3 2025), 0.22 (Q1 2025), and 0.18 (Q4 2024).